Get started

Financials · GOSS

Gossamer Bio Inc. (GOSS) financials

For the twelve months ended Jun 30, 2026, Gossamer Bio Inc. reported $53.29M of revenue and -$125.22M of net income.

Revenue, TTM
$53.29M
Revenue growth, YoY
+32.4%
Net income, TTM
-$125.22M
Net margin
-235.0%
Free cash flow, TTM
-$162.63M
EPS, diluted, TTM
-$0.70
Cash
$41.15M
P/S
1.12
Market cap
$59.8M
Annual revenue$48.47M
FY2022FY2025
Annual net income-$170.37M
FY2017FY2025
Annual free cash flow-$171.34M
FY2018FY2025

GOSS revenue and earnings growth

GOSS revenueQ2 2026$9.24M

Quarter YoY
-19.6%
QoQ
-45.5%
FY YoY
-57.7%

GOSS revenue was $9.24M in fiscal Q2 2026 (ended Jun 30, 2026), down 19.6% from a year earlier and down 45.5% from the prior quarter. For the full fiscal 2025 it was $48.47M, down 57.7% from fiscal 2024.

GOSS net incomeQ2 2026$16.90M

GOSS net income was $16.90M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$38.27M a year earlier. For the full fiscal 2025 it was -$170.37M, compared with -$56.53M in fiscal 2024.

GOSS EPSQ2 2026-$0.08

GOSS diluted EPS was -$0.08 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.75, compared with -$0.25 in fiscal 2024.

GOSS free cash flowQ2 2026-$39.42M

GOSS free cash flow was -$39.42M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$47.11M a year earlier. For the full fiscal 2025 it was -$171.34M, compared with -$3.47M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue$48.47M$114.70M$0$0-----
Research and development$174.09M$138.49M$135.30M$170.92M$170.27M$160.85M$143.40M$55.28M$891.0K
Selling, general and admin$37.63M$36.13M$38.45M$47.61M$45.78M$49.73M$39.14M$44.05M$262.0K
Operating income-$170.73M-$59.92M-$183.76M-$218.59M-$216.12M-$233.96M-$186.14M-$148.99M-$6.65M
Interest expense$10.99M$11.52M$13.51M$13.88M$19.44M$12.67M$1.94M$12.0K-
Pre-tax income-$170.46M-$55.63M-$179.82M-$229.38M-$234.00M-$243.36M-$180.31M-$146.97M$6.77M
Income tax-$88.0K$893.0K$0$0--$0$0$0
Net income-$170.37M-$56.53M-$179.82M-$229.38M-$234.00M-$243.36M-$180.31M-$146.97M-$6.77M
EPS, basic-$0.75-$0.25-$1.18-$2.71-$3.13-$3.55-$3.29-$22.59-$0.74
EPS, diluted-$0.75-$0.25-$1.18-$2.71-$3.13-$3.55-$3.29-$22.59-$0.74
Diluted shares228.5M226.2M152.6M84.6M74.8M68.5M54.7M6.5M9.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalents$37.73M$46.07M$32.11M$111.97M$183.47M$486.62M$135.09M$105.42M$315.0K
Short-term investments$99.20M$248.44M$264.32M$143.71M$141.81M$26.57M$266.74M$123.44M-
Receivables$12.23M$5.34M$0------
Current assets$167.64M$309.89M$306.52M$261.88M$331.78M$522.32M$409.32M$231.95M-
Total assets$172.25M$315.29M$311.92M$272.45M$343.66M$539.43M$426.60M$239.42M-
Current liabilities$63.44M$45.01M$51.60M$49.23M$39.86M$38.65M$36.92M$20.40M-
Short-term debt-$0$11.61M$11.61M$0----
Long-term debt-$0$814.0K$11.99M$29.08M$28.74M$28.46M--
Total debt-$0$12.43M$23.60M$29.08M$28.74M$28.46M--
Total liabilities$295.01M$285.80M$249.15M$260.37M$222.19M$218.75M$74.12M$21.12M-
Shareholders' equity-$122.76M$29.49M$62.77M$12.08M$121.46M$320.68M$352.49M-$120.07M-$6.86M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-$171.27M-$3.47M-$159.16M-$187.03M-$188.89M-$176.36M-$144.83M-$51.04M-$5.75M
Capital expenditures$79.0K$0$0$410.0K$1.55M$1.50M$2.97M$3.49M-
Free cash flow-$171.34M-$3.47M-$159.16M-$187.44M-$190.44M-$177.86M-$147.80M-$54.53M-
Investing cash flow$156.36M$29.02M-$110.97M-$1.03M-$117.43M$215.34M-$147.14M-$144.71M-
Financing cash flow$6.42M-$11.49M$190.15M$117.09M$3.33M$312.54M$321.58M$300.86M$6.00M
Stock-based compensation$10.55M$20.62M$28.52M$42.55M$32.01M$38.75M$20.82M$30.95M$32.0K
Depreciation and amortization$24.0K$833.0K$1.61M$1.83M$1.74M$1.41M$917.0K$297.0K-

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY-57.7%--------
Operating margin-352.2%-52.2%-------
Net margin-351.5%-49.3%-------
Free cash flow margin-353.5%-3.0%-------
Return on equity--191.7%-286.5%-1899.3%-192.7%-75.9%-51.2%--
Return on assets-98.9%-17.9%-57.6%-84.2%-68.1%-45.1%-42.3%-61.4%-
Current ratio2.646.885.945.328.3213.5111.0911.37-
Debt to equity-0.000.201.950.240.090.08--

Source: XBRL data Gossamer Bio Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

GOSS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
GOSS$53.29M+32.4%-$125.22M-235.0%$59.8M
CABA---$189.50M-$221.3M
PALI$500.0K--$31.94M-6388.2%$196.9M
TIL$8.97M+2.5%-$30.28M-337.7%$46.3M
INMB$50.0K+257.1%-$45.93M-91866.0%$35.0M
PASG---$36.11M-$12.8M

GOSS FAQ

8 questions
  • What is GOSS revenue?
    Gossamer Bio Inc. (GOSS) reported $53.29M of revenue for the twelve months ended Jun 30, 2026. That is up 32.4% from the year before. Revenue for fiscal 2025 was $48.47M.
  • Is GOSS profitable?
    No. Gossamer Bio Inc. reported a net loss of $125.22M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does GOSS have?
    Gossamer Bio Inc. reported $41.15M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is GOSS revenue growing?
    Gossamer Bio Inc.'s revenue changed -57.7% in fiscal 2025, to $48.47M.
  • What is GOSS free cash flow?
    Gossamer Bio Inc. generated -$162.63M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$162.63M less capital expenditures.
  • What is GOSS earnings per share?
    Diluted earnings per share were -$0.70 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did GOSS last report financial results?
    The latest statements here come from Gossamer Bio Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this GOSS financial data come from?
    Quantisnow builds these statements from the structured XBRL data Gossamer Bio Inc. files with the SEC. It is provided for information only and is not investment advice.